KR20180127780A - Chinese medicine for treating hyperostosis - Google Patents
Chinese medicine for treating hyperostosis Download PDFInfo
- Publication number
- KR20180127780A KR20180127780A KR1020170062951A KR20170062951A KR20180127780A KR 20180127780 A KR20180127780 A KR 20180127780A KR 1020170062951 A KR1020170062951 A KR 1020170062951A KR 20170062951 A KR20170062951 A KR 20170062951A KR 20180127780 A KR20180127780 A KR 20180127780A
- Authority
- KR
- South Korea
- Prior art keywords
- chinese medicine
- weight
- bone
- treatment
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 201000010934 exostosis Diseases 0.000 title claims description 19
- 201000010930 hyperostosis Diseases 0.000 title claims description 19
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 40
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 13
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 13
- 241001494479 Pecora Species 0.000 claims abstract description 12
- 241000208689 Eucommia ulmoides Species 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 229940126678 chinese medicines Drugs 0.000 claims description 4
- 241000255925 Diptera Species 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 241000548230 Crassostrea angulata Species 0.000 claims description 2
- 241001489978 Eupolyphaga Species 0.000 claims description 2
- 241000405414 Rehmannia Species 0.000 claims description 2
- VPWFPZBFBFHIIL-UHFFFAOYSA-L disodium 4-[(4-methyl-2-sulfophenyl)diazenyl]-3-oxidonaphthalene-2-carboxylate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 VPWFPZBFBFHIIL-UHFFFAOYSA-L 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 241001489980 Eupolyphaga sinensis Species 0.000 abstract 1
- 241000229182 Ledebouriella seseloides Species 0.000 abstract 1
- 241000405911 Rehmannia glutinosa Species 0.000 abstract 1
- 241000800405 Spatholobus suberectus Species 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 21
- 239000000843 powder Substances 0.000 description 21
- 238000009835 boiling Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 244000281702 Dioscorea villosa Species 0.000 description 8
- 235000004879 dioscorea Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 238000010298 pulverizing process Methods 0.000 description 7
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 210000000629 knee joint Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 4
- 206010005963 Bone formation increased Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010023230 Joint stiffness Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 241001346334 Amomum tsao-ko Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 235000005903 Dioscorea Nutrition 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000062241 Kaempferia galanga Species 0.000 description 1
- 235000013421 Kaempferia galanga Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 208000007771 sciatic neuropathy Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Insects & Arthropods (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 뼈과다증 (hyperostosis)의 치료를 위한 중국 약제에 관한 것이다. The present invention relates to a Chinese medicine for the treatment of hyperostosis.
증식 뼈 관절염 (proliferative bone arthritis), 골관절염 (osteoarthritis: OA), 퇴행 관절증 (degenerative arthrosis), 노인 관절염 (senile arthritis), 비후관절염 (hypertrophiarthritis)으로 또한 알려져 있는 뼈과다증은 관절에 과도한 부하의 사례에서, 관절통 (arthralgia), 운동 제한 (limitation of motion) 등의 증상을 갖는 질환이며, 연골, 추간판 (intervertebral disc), 인대 (ligament) 및 기타 연조직의 퇴행 (degeneration) 및 퇴화 (retrogression)에 의해서, 뼈돌기 (bony spur) 및 윤활막 (synovium)의 비대 (thickening)가 관절 가장자리에서 나타나서, 뼈를 파괴하고 후속적으로 뼈 과다형성 (bone hyperplasia) 및 관절기형 (dysarthrasis)을 일으킨다. 뼈과다증은 1차 뼈과다증 및 2차 뼈과다증의 2가지 타입이 있다. 효과적인 치료법은 없고, 유일한 방법은 다량의 칼슘을 보충하는 것이다.Bone hypertrophy, also known as proliferative bone arthritis, osteoarthritis (OA), degenerative arthrosis, senile arthritis, and hypertrophiarthritis, is a common complication of joint overload, Arthralgia, limitation of motion, and the like. By degeneration and retrogression of cartilage, intervertebral disc, ligament, and other soft tissues, thickening of the bony spur and synovium occurs at the joint edge, destroying the bones and subsequently causing bone hyperplasia and dysarthrasis. There are two types of bone hyperplasia: primary bone hyperplasia and secondary bone hyperplasia. There is no effective cure, and the only way is to supplement a large amount of calcium.
증상 및 증후:Symptoms and symptoms:
1. 경추 뼈과다성장 (cervical vertebral hyperosteogeny):1. Cervical vertebral hyperosteogeny:
임상 증상: 목 경직 (neck stiffness), 운동 제한, 목 움직임의 경우에 클릭음 (click in case of neck movement), 어깨 및 상지로 퍼지는 통증 (pain radiating to shoulder and upper limb), 저린감 (numbness) 및, 손과 손가락에서 전기-충격과 같은 느낌 (electric shock-like feeling)이 목 움직임에 의해서 악화되고, 다른 증상으로 나타나는 다른 부분과 관련된 다른 병변, 최종 단계에서 마비를 일으킬 수 있고; 경추 뼈과다성장 중증 환자는 경추증 고혈압 (cervical spondylosis hypertension), 심장혈관 및 뇌혈관 질환, 위염, 협심증 (angina), 삼킴 곤란 (dysphagia) 등을 더 갖는다.Clinical symptoms include: neck stiffness, limitation of movement, click in case of neck movement, pain radiating to shoulder and upper limb, numbness, And electric shock-like feeling in the hands and fingers may be exacerbated by neck movements, other lesions associated with other parts appearing as other symptoms, paralysis in the final stages; Severe hypertrophic cervical vertebrae further have cervical spondylosis hypertension, cardiovascular and cerebrovascular disease, gastritis, angina, dysphagia, and the like.
2. 요추 뼈과다성장 (lumbar vertebral hyperosteogeny):2. Lumbar vertebral hyperosteogeny:
원발 부위는 가장 일반적으로 3번 및 4번 요추이다; 임상 증상은 요추 및 허리 연조직의 쑤시는 통증 (aching pain), 부종 통증 (swelling pain), 경직 및 피로, 규칙적인 구부림의 제한 (even bend limitation)이 있고; 인접한 신경근이 눌린다면, 국소 통증, 경직, 후근 신경통 (dorsal root neuralgia), 저린감 등의 상응하는 증상을 유발할 것이다; 좌골 신경 (sciatic nerve)이 눌린다면, 좌골 신경염 (sciatic neuritis), 중증 저림 및 통증의 발생, 작열통 (causalgia), 박동 통증 (throbbing pain) 및 이환된 사지 (affected limb)에서 전체 하지 (lower limb)로 퍼지는 이동 통증 (wandering pain)을 유발할 것이다.The primary site is most commonly the 3rd and 4th lumbar spine; Clinical symptoms include aching pain, swelling pain, stiffness and fatigue of the lumbar and waist soft tissues, and even bend limitation; If adjacent nerve roots are squeezed, they will cause corresponding symptoms such as local pain, stiffness, dorsal root neuralgia, jerkiness, etc.; If the sciatic nerve is depressed, the lower limb is removed from the sciatic neuritis, the occurrence of severe stiffness and pain, causalgia, throbbing pain and affected limb, Gt; wandering < / RTI >
3. 무릎 관절 뼈과다성장 (knee-joint hyperosteogeny):3. Knee-joint hyperosteogeny:
초기 단계에서, 발병이 느린 환자는 심각한 무릎 관절 통증을 갖지 않지만, 그러나 계속되는 둔통 (dull pain)을 갖는다; 기후 변화에 따라서, 기온이 떨어지면 통증이 악화되고; 아침 움직임 시작 시에, 장시간 걸은 후에, 격렬한 운동의 경우 또는 장시간 앉아 있다가 걷기 시작한 경우에, 환자는 무릎 관절 통증 및 경직을 갖지만, 그러나 약간 움직인 후에 더 나아진다; 환자들은 계단을 오르거나 또는 내려가는 것이 어렵고, 무릎 관절이 약해져서, 계단을 내려갈 때 쉽게 넘어진다; 웅크린 상태 (squatting)에서 일어나는 경우, 무릎 관절 통증 및 경직이, 심각한 경우에, 무릎 관절 앓이 (soring) 및 부종 통증, 및 절름발이 (limping)가 있고; 또한 류마티스가 있는 환자에 있어서, 무릎 관절이 빨개지고, 붓고, 비정상이며, 기능적으로 제한이 있다; 무릎 관절을 스트레칭하거나 구부릴 때 클릭음이 있다; 일부 환자는 관절 수종 (join thydrops)을 가지며, 관절의 국소 부위에서 명백한 부종 및 압박 (compression)을 갖는다.In the early stages, patients with slow onset do not have severe knee pain, but continue to have dull pain; Depending on climate change, the temperature gets worse when the temperature drops; The patient has knee joint pain and stiffness, but after a few moves he gets better, at the start of morning movements, after a long walk, in intense exercise, or if he starts to sit and walk for a long time; Patients are difficult to climb or descend a stairway, knee joints weaken and fall easily when going down stairs; When it occurs in squatting, there are knee joint pain and stiffness, in severe cases, soring and edema pain, and limping; In patients with rheumatism, the knee joints are reddish, swollen, abnormal, and functionally restricted; There are clicks when stretching or bending the knee joint; Some patients have joint thydrops and have obvious edema and compression at the local area of the joint.
양 (sheep)의 뼈는 칼슘 포스페이트, 칼슘 카르보네이트 및 콜라겐을 포함한다. 이는 간을 따뜻하게 하는 특성 및 풍미와, 신장 및 근육을 향상시키는 효과를 갖는다. 이는 저혈소판증 자간 (thrombocytopenia eclampsia), 재생불량빈혈 (aplastic anemia), 관절통 (arthralgia) 및 근육통 (myalgia), 허리 약화 (waist weakening), 임질 (gonorrhea), 통증배뇨 (stranguria), 만성 설사 (chronic diarrhea), 지속되는 이질 (lingering dysentery) 등의 질환의 치료에 사용될 수 있다. Yin Shi Zheng Yao라는 책에서, 한쌍의 양의 뼈 (절단), 건조된 귤 껍질 (tangerine peel) 6g, 고량강 (galangal) 6g, 초과 (Amomum tsaoko) 6g, 신선한 생강 (fresh ginger) 30g, 및 약간의 소금 (salt)과, 물로 조리하여 제조된 양뼈의 죽 (sheep bone porridge)은 소모 (consumption) 및 허리 약화 (waist weakness)를 치료하는데 양호한 효과를 갖는다고 기록되어 있다.Bones of sheep include calcium phosphate, calcium carbonate and collagen. This has the effect of warming the liver and improving the characteristics and flavor, kidney and muscle. These include thrombocytopenia eclampsia, aplastic anemia, arthralgia and myalgia, waist weakening, gonorrhea, stranguria, chronic diarrhea, diarrhea, lingering dysentery, and the like. In a book called Yin Shi Zheng Yao, a pair of sheep bone, 6 grams of dried tangerine peel, 6 grams of galangal, 6 grams of Amomum tsaoko, 30 grams of fresh ginger, It has been reported that some salt and sheep bone porridge prepared by cooking with water have good effects in treating consumption and waist weakness.
그러므로, 뼈과다증을 치료하기 위한 주요 물질 성분으로 양의 뼈를 갖는 중국 약제를 개발하는 것이 필요하다.Therefore, it is necessary to develop Chinese medicines having positive bones as a major substance component for treating bone hypertrophy.
본 발명의 목적은 양호한 포괄적 약제 특성 및 개발 효과를 가지며, 전통 약제 물질의 효과와 현대 약리학의 연구 성과를 조합함으로써 제조되는, 주요 성분으로서 양의 뼈를 갖는 중국 약제를 제공하는데 있다. It is an object of the present invention to provide a Chinese medicine having good bodily bone as a main ingredient which is produced by combining good pharmacological properties and development effects and the effects of traditional pharmaceutical substances and research results of modern pharmacology.
한편, 본 발명은 뼈과다증을 치료하기 위한 중국 약제를 제공하고, 이는 중량부로: 양의 뼈 20-30, 지황 (Rhizome of rehmannia) 10-20, 두충 (Eucommia ulmoides) 10-20, 홍화 (Carthamus tinctorius) 5-10, 계혈등 (Caulis Spatholobi) 5-10, 방풍 (Radix Saposhnikoviae) 4-8, 및 토별충 (Eupolyphaga seu Steleophaga) 3-9로부터 제조되는 것을 특징으로 한다.Meanwhile, the present invention provides a Chinese medicine for treating bone hyperplasia, which comprises 20 to 30 parts by weight of bone, Rhizome of rehmannia 10-20, Eucommia ulmoides 10-20, Carthamus Tinctorius 5-10, Caulis Spatholobi 5-10, Radix Saposhnikoviae 4-8, and Eupolyphaga seu Steleophaga 3-9.
상기 중국 약제의 제조 방법은 하기 단계를 포함한다:The method of manufacturing the Chinese medicine comprises the following steps:
물질 준비 단계 (Material preparing step): 중량부로: 양의 뼈 20-30, 참마 (Dioscorea opposite) 10-20, 두충 10-20, 홍화 5-10, 계혈등 5-10, 방풍 4-8, 토별충 3-9를 준비하는 단계;Material preparing step: Weighing parts: 20-30 for sheep bone, 10-20 for dioscorea opposite, 10-20 for mite, 5-10 for safflower, 5-10 for blood, Preparing preparations 3-9;
분쇄 단계 (Crushing step): 상기 성분들을 균일하게 혼합하고, 분말로 분쇄하는 단계;Crushing step: uniformly mixing the components and pulverizing into powders;
달이는 단계 (Decocting step): 상기 분말들을, 상기 분말 중량부의 10-20배의 끓는 물에 넣고, 3-5분 동안 끓인 후에, 뼈과다증을 치료하기 위한 본 발명의 중국 약제를 수득하기 위해서, 감소된 온도에서 30-50분 동안 달이는 단계.Decocting step: The powders are placed in boiling water 10-20 times the weight of the powder, boiled for 3-5 minutes, and then reduced to obtain the Chinese medicine of the present invention for treating bone hyperplasia. Lt; / RTI > for 30-50 minutes.
본 발명의 중국 약제의 적용 방법은 하기를 포함한다:Methods of application of the Chinese medicaments of the present invention include:
외용 적용 (external application): 상기 이환 부위에 상기 중국 약제를 1일 3회 5일의 치료 과정 동안 균일하게 적용한다;External application: The Chinese medicine is uniformly applied to the affected area three times a day for 5 days of treatment;
경구 투여 (oral administration): 50 ml의 상기 중국 약제를 취하고, 40 ml의 따뜻한 끓인 물에 혼합하고, 균일하게 교반하여, 복용한다.Oral administration: Take 50 ml of the above Chinese medicine, mix in 40 ml of warm boiled water, and mix uniformly.
상기 제조에 사용된 상기 성분 물질들의 의학적 특성은 하기와 같다:The medical properties of the ingredient materials used in the preparation are as follows:
양의 뼈 (sheep bone): 양의 뼈는 칼슘 포스페이트, 칼슘 카르보네이트 및 콜라겐을 포함하고; 간을 따뜻하게 하는 특성 및 풍미와, 신장 및 근육을 향상시키는 효과를 가지며; 저혈소판증 자간, 재생불량빈혈, 관절통 및 근육통, 허리 약화, 임질, 통증배뇨, 만성 설사, 지속되는 이질 등의 질환에 적용될 수 있다. 뼈의 화학적 성분은 그 부위 및 연령에 따라 상이하다. 성분들 중에, 가장 명백한 차이점은 수분과 지질이다. 상기 뼈는 그 안에 다량의 무기 물질 (inorganic substances)을 포함하고, 칼슘 포스페이트가 반 이상을 차지한다. 또한, 상기는 소량의 칼슘 카르보네이트, 마그네슘 포스페이트 및 미량의 불소, 염소, 나트륨, 칼륨, 철, 알루미늄 등을 포함한다. 불소 함량이 적음에도 불구하고, 이는 상기 뼈의 중요 성분이다. 상기 뼈 안에 함유된 유기 물질 (organic substances)은 콜라겐, 오세오뮤코이드 (osseomucoid), 엘라스티신-유사 (elasticin-like) 물질이고; 또한 중성 지방 (함량이 많음), 포스포리피드 (phospholipid) 및 적은 양의 글리코겐 (glycogen) 등이 있다.Sheep bone: The positive bone contains calcium phosphate, calcium carbonate and collagen; Has the characteristics and flavor of warming the liver, and has the effect of improving kidney and muscle; Low platelet hypertrophy, poorly regenerating anemia, arthralgia and myalgia, weakness in the back, gonorrhea, pain urination, chronic diarrhea, persistent dysentery, and the like. The chemical composition of the bone varies depending on the site and age. Among the ingredients, the most obvious difference is moisture and lipid. The bone contains a large amount of inorganic substances therein, and calcium phosphate accounts for more than half of the bone. It also includes small amounts of calcium carbonate, magnesium phosphate and trace amounts of fluorine, chlorine, sodium, potassium, iron, aluminum and the like. Despite the low fluoride content, it is an important component of the bone. The organic substances contained in the bone are collagen, osseomucoid, and elasticin-like substances; There are also triglycerides (high in content), phospholipids and low amounts of glycogen.
뼈과다증을 치료하기 위한 본 발명의 중국 약제는 1차 및 2차 뼈과다증의 치료의 억제 효과를 가지며, 또한, 본 발명은 통증을 완화하고, 관절 운동 능력을 강화하는 부가의 기술적 효과를 갖는다. 본 발명의 중국 약제는 외용으로 적용되고, 또한 경구로 복용될 수 있고; 또한 외용 적용을 경구 투여와 조합하여 더 좋은 치료 효과를 달성할 것이다.The Chinese medicine of the present invention for treating bone hypertrophy has an inhibitory effect on the treatment of primary and secondary bone hyperplasia, and the present invention also has an additional technical effect of alleviating pain and enhancing joint motion ability. The Chinese medicine of the present invention is applied for external use and can also be taken orally; In addition, topical application may be combined with oral administration to achieve a better therapeutic effect.
본 발명의 다른 특성 및 장점이 하기 구현예들로부터 상세하게 서술될 것이다.Other features and advantages of the invention will be described in detail from the following embodiments.
일반성을 잃지 않고, 본 발명은 뼈과다증을 치료하기 위한 중국 약제를 제공하고, 그 물질 성분들은 중량부로: 양의 뼈 20-30, 참마 10-20, 두충 10-20, 홍화 5-10, 계혈등 5-10, 방풍 4-8, 토별충 3-9를 포함한다.Without losing the generality, the present invention provides a Chinese medicine for treating bone hyperplasia, wherein the substance components are in parts by weight: positive bone 20-30, yam 10-20, mosquito 10-20, safflower 5-10, 5-10, 4-8, and 3-9.
상기 중국 약제의 제조 방법은 하기 단계를 포함한다:The method of manufacturing the Chinese medicine comprises the following steps:
물질 준비 단계: 중량부로: 양의 뼈 20-30, 참마 10-20, 두충 10-20, 홍화 5-10, 계혈등 5-10, 방풍 4-8, 토별충 3-9를 준비하는 단계;Preparation stage of material: Prepare for 20-30 weight loss, 10-20 yam, 10-20 mushroom, 10-20 mushroom, 5-10 mushroom, 5-10 mushroom, 4-8 mushroom, 3-9 mushroom.
분쇄 단계: 상기 성분들을 균일하게 혼합하고, 분말로 분쇄하는 단계;Grinding step: uniformly mixing the components and pulverizing into powder;
달이는 단계: 상기 분말들을, 상기 분말의 중량부의 10-20배의 끓는 물에 넣고, 3-5분 동안 끓인 후에, 뼈과다증을 치료하기 위한 본 발명의 중국 약제를 수득하기 위해서, 감소된 온도에서 30-50분 동안 달이는 단계.Draining step: The powders are placed in boiling water 10-20 times the weight of the powder, boiled for 3-5 minutes and then cooled at a reduced temperature to obtain a Chinese medicine of the present invention for treating bone hypertrophy Steps that hang for 30-50 minutes.
본 발명의 중국 약제의 적용 방법은 하기를 포함한다:Methods of application of the Chinese medicaments of the present invention include:
외용 적용: 상기 이환 부위에 상기 중국 약제를 1일 3회, 5일의 치료 과정 동안, 균일하게 적용한다;Externally applied: The Chinese medicine is uniformly applied to the affected area 3 times a day for 5 days of treatment;
경구 투여: 50 ml의 상기 중국 약제를 취하고, 40 ml의 따뜻한 끓인 물에 혼합하고, 균일하게 교반하여, 복용한다.Oral administration: Take 50 ml of the above-mentioned Chinese medicine, mix in 40 ml of warm boiled water, and mix uniformly.
뼈과다증을 치료하기 위한 본 발명의 중국 약제는 1차 및 2차 뼈과다증의 치료의 억제 효과를 가지며, 또한, 본 발명은 통증을 완화하고, 관절 운동 능력을 강화하는 부가의 기술적 효과를 갖는다. 본 발명의 중국 약제는 외용으로 적용되고, 또한 경구로 복용될 수 있고; 또한 외용 적용을 경구 투여와 조합하여 더 좋은 치료 효과를 달성할 것이다.The Chinese medicine of the present invention for treating bone hypertrophy has an inhibitory effect on the treatment of primary and secondary bone hyperplasia, and the present invention also has an additional technical effect of alleviating pain and enhancing joint motion ability. The Chinese medicine of the present invention is applied for external use and can also be taken orally; In addition, topical application may be combined with oral administration to achieve a better therapeutic effect.
본 발명은 하기 실시예에 의해서 더 상세히 서술된다.The present invention is described in more detail by the following examples.
실시예 1Example 1
경증 1차 뼈과다증 (mild primary hyperostosis)의 치료:Treatment of mild primary hyperostosis:
뼈과다증을 치료하기 위한 본 발명의 중국 약제가, 양의 뼈 20g, 참마 10g, 두충 10g, 홍화 5g, 계혈등 5g, 방풍 4g, 토별충 3g을 취하고; 상기 성분들을 균일하게 혼합하고, 이를 분말로 분쇄하고; 상기 분말들을, 상기 분말 중량부의 10-20배의 끓는 물에 넣고, 3-5분 동안 끓이고, 또한 감소된 온도에서 30-50분 동안 달임으로써 수득된다.The Chinese medicine of the present invention for treating bone hypertrophy takes 20 g of sheep bone, 10 g of yam, 10 g of mugwort, 5 g of safflower, 5 g of blood, 5 g of windshield, Uniformly mixing the components, pulverizing them into powder; The powders are obtained by adding 10-20 times the weight of the powder to boiling water, boiling for 3-5 minutes, and also reducing for 30-50 minutes at reduced temperature.
상기 중국 약제가 상기 이환 부위에 1일 3회, 5일의 치료 과정 동안 균일하게 적용되고; 3회의 치료 과정 후에 통증이 뚜렷하게 완화되었고; 8회의 치료 과정 후에 통증이 제거되었으며; 또한 15회의 치료 과정 동안 연속 적용 후에 치료되었다.Wherein said Chinese medicament is applied uniformly to said bifurcation site during a three-day, five-day course of treatment; Pain was markedly relieved after three treatment courses; Pain was removed after 8 treatment courses; It was also treated after 15 consecutive treatment sessions.
실시예 2:Example 2:
중등도 1차 뼈과다증 (moderate primary hyperostosis)의 치료:Treatment of moderate primary hyperostosis:
뼈과다증을 치료하기 위한 본 발명의 중국 약제가, 양의 뼈 22g, 참마 10g, 두충 13g, 홍화 6g, 계혈등 6g, 방풍 4g, 토별충 3g을 취하고; 상기 성분들을 균일하게 혼합하고, 이를 분말로 분쇄하고; 상기 분말들을, 상기 분말 중량부의 10-20배의 끓는 물에 넣고, 3-5분 동안 끓이고, 또한 감소된 온도에서 30-50분 동안 달임으로써 수득된다.Chinese medicine of the present invention for treating bone hypertrophy takes 22 g of sheep bone, 10 g of yam, 13 g of mugwort, 6 g of safflower, 6 g of blood, 6 g of windbreak, Uniformly mixing the components, pulverizing them into powder; The powders are obtained by adding 10-20 times the weight of the powder to boiling water, boiling for 3-5 minutes, and also reducing for 30-50 minutes at reduced temperature.
바람직하게, 본 실시예의 하나의 바람직한 기술적 해결책에서, 상기 물질 성분들은 또한 강황 (Rhizoma Curcumae) 4g 및 모려 (Ostrea gigas) 5g을 포함한다.Preferably, in one preferred technical solution of this embodiment, the material components also comprise 4 g of Rhizoma Curcumae and 5 g of Ostrea gigas.
상기 중국 약제가 상기 이환 부위에 1일 3회, 5일의 치료 과정 동안, 균일하게 적용되고; 4회의 치료 과정 후에 통증이 뚜렷하게 완화되었고; 10회의 치료 과정 후에 통증이 제거되었으며; 또한 20회의 치료 과정 동안 연속 적용 후에 치료되었다.Wherein said Chinese medicament is applied uniformly to said bifurcation site during a treatment period of 3 times a day for 5 days; Pain was markedly relieved after 4 treatment courses; Pain was removed after 10 treatment courses; It was also treated after continuous application for 20 treatment courses.
실시예 3:Example 3:
중증 1차 뼈과다증 (severe primary hyperostosis)의 치료:Treatment of severe primary hyperostosis:
뼈과다증을 치료하기 위한 본 발명의 중국 약제가, 양의 뼈 25g, 참마 15g, 두충 15g, 홍화 7g, 계혈등 8g, 방풍 6g, 토별충 6g을 취하고; 상기 성분들을 균일하게 혼합하고, 이를 분말로 분쇄하고; 상기 분말들을, 상기 분말 중량부의 10-20배의 끓는 물에 넣고, 3-5분 동안 끓이고, 또한 감소된 온도에서 30-50분 동안 달임으로써 수득된다.Chinese medicine of the present invention for treating bone hypertrophy takes 25 grams of sheep bone, 15 grams of yam, 15 grams of bamboo shoots, 7 grams of safflower, 8 grams of bloodshed, 6 grams of windshield, Uniformly mixing the components, pulverizing them into powder; The powders are obtained by adding 10-20 times the weight of the powder to boiling water, boiling for 3-5 minutes, and also reducing for 30-50 minutes at reduced temperature.
바람직하게, 본 실시예의 하나의 바람직한 기술적 해결책에서, 상기 물질 성분들은 또한 강황 5g 및 모려 8g을 포함한다.Preferably, in one preferred technical solution of this embodiment, the material components also contain 5 g of turmeric and 8 g of boric acid.
상기 중국 약제가 상기 이환 부위에 1일 3회 균일하게 적용되고; 50 ml의 상기 중국 약제가 따뜻한 끓인 물에 혼합되고, 균일하게 혼합된 후에 1일 4회, 5일의 치료 과정 동안 복용되고; 4회의 치료 과정 후에 통증이 뚜렷하게 완화되었고; 10회의 치료 과정 후에 통증이 제거되었으며; 또한 20회의 치료 과정 동안 연속 적용 후에 치료되었다.Wherein said Chinese medicine is uniformly applied to said affected area three times a day; 50 ml of the above-mentioned Chinese medicines are mixed in warm boiled water, and are uniformly mixed and then taken for 4 times a day for 5 days during the course of treatment; Pain was markedly relieved after 4 treatment courses; Pain was removed after 10 treatment courses; It was also treated after continuous application for 20 treatment courses.
실시예 4Example 4
중증 2차 뼈과다증 (severe secondary hyperostosis)의 치료:Treatment of Severe Secondary Hyperostosis:
뼈과다증을 치료하기 위한 본 발명의 중국 약제가, 양의 뼈 28g, 참마 16g, 두충 18g, 홍화 9g, 계혈등 8g, 방풍 8g, 토별충 8g을 취하고; 상기 성분들을 균일하게 혼합하고, 이를 분말로 분쇄하고; 상기 분말들을, 상기 분말 중량부의 10-20배의 끓는 물에 넣고, 3-5분 동안 끓이고, 또한 감소된 온도에서 30-50분 동안 달임으로써 수득된다.The Chinese medicine of the present invention for treating bone hypertrophy takes 28 g of sheep bone, 16 g of yam, 18 g of mosquito, 9 g of safflower, 8 g of blood, 8 g of wind, Uniformly mixing the components, pulverizing them into powder; The powders are obtained by adding 10-20 times the weight of the powder to boiling water, boiling for 3-5 minutes, and also reducing for 30-50 minutes at reduced temperature.
바람직하게, 본 실시예의 하나의 바람직한 기술적 해결책에서, 상기 물질 성분들은 또한 강황 6g 및 모려 12g을 포함한다.Preferably, in one preferred technical solution of this embodiment, the material components also comprise 6 g of turmeric and 12 g of corn.
상기 중국 약제가 상기 이환 부위에 1일 3회 균일하게 적용되고; 50 ml의 상기 중국 약제가 따뜻한 끓인 물에 혼합되고, 균일하게 혼합된 후에 1일 4회, 5일의 치료 과정 동안 복용되고; 4회의 치료 과정 후에 통증이 뚜렷하게 완화되었고; 10회의 치료 과정 후에 통증이 제거되었으며; 또한 20회의 치료 과정 동안 연속 적용 후에 치료되었다.Wherein said Chinese medicine is uniformly applied to said affected area three times a day; 50 ml of the above-mentioned Chinese medicines are mixed in warm boiled water, and are uniformly mixed and then taken for 4 times a day for 5 days during the course of treatment; Pain was markedly relieved after 4 treatment courses; Pain was removed after 10 treatment courses; It was also treated after continuous application for 20 treatment courses.
실시예 5Example 5
경증 또는 중등도 2차 뼈과다증 (mild or moderate secondary hyperostosis)의 치료:Treatment of mild or moderate secondary hyperostosis:
뼈과다증을 치료하기 위한 본 발명의 중국 약제가, 양의 뼈 30g, 참마 20g, 두충 20g, 홍화 10g, 계혈등 10g, 방풍 8g, 토별충 9g을 취하고; 상기 성분들을 균일하게 혼합하고, 이를 분말로 분쇄하고; 상기 분말들을, 상기 분말 중량부의 10-20배의 끓는 물에 넣고, 3-5분 동안 끓이고, 또한 감소된 온도에서 30-50분 동안 달임으로써 수득된다.The Chinese medicine of the present invention for treating bone hypertrophy takes 30 grams of sheep bone, 20 grams of yam, 20 grams of bamboo shoots, 10 grams of safflower, 10 grams of bloodshed, 8 grams of windshield, Uniformly mixing the components, pulverizing them into powder; The powders are obtained by adding 10-20 times the weight of the powder to boiling water, boiling for 3-5 minutes, and also reducing for 30-50 minutes at reduced temperature.
상기 중국 약제가 상기 이환 부위에 1일 3회, 5일의 치료 과정 동안 균일하게 적용되고; 4회의 치료 과정 후에 통증이 뚜렷하게 완화되었고; 8회의 치료 과정 후에 통증이 제거되었으며; 또한 15회의 치료 과정 동안 연속 적용 후에 치료되었다.Wherein said Chinese medicament is applied uniformly to said bifurcation site during a three-day, five-day course of treatment; Pain was markedly relieved after 4 treatment courses; Pain was removed after 8 treatment courses; It was also treated after 15 consecutive treatment sessions.
상기 시험 실시예로부터, 본 발명의 중국 약제 화합물이 뼈과다증에서 특별한 효과를 가질 수 있다는 것을 볼 수 있다. 통계에 따르면, 어떤 형태의 뼈과다증을 갖는 거의 200명의 환자가 본 발명의 중국 약제를 적용한 후에 효과적으로 치료될 수 있다. 또한, 상기는 적용 후에 피부 자극을 일으키지 않고, 경구 투여 후에 거의 부작용을 갖지 않았다.From these test examples it can be seen that the Chinese pharmaceutical compounds of the present invention may have a special effect in bone hyperplasia. According to statistics, nearly 200 patients with some form of bone hypertrophy can be effectively treated after applying the Chinese medicine of the present invention. In addition, it did not cause skin irritation after application and had almost no side effects after oral administration.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170062951A KR20180127780A (en) | 2017-05-22 | 2017-05-22 | Chinese medicine for treating hyperostosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170062951A KR20180127780A (en) | 2017-05-22 | 2017-05-22 | Chinese medicine for treating hyperostosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180127780A true KR20180127780A (en) | 2018-11-30 |
Family
ID=64561086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170062951A Ceased KR20180127780A (en) | 2017-05-22 | 2017-05-22 | Chinese medicine for treating hyperostosis |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20180127780A (en) |
-
2017
- 2017-05-22 KR KR1020170062951A patent/KR20180127780A/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103239520A (en) | Moslemic ointment for treating osteoarthritis and preparation method of moslemic ointment | |
| CN103735791B (en) | A kind of Chinese medicine composition and preparation method thereof for the treatment of lumbar vertebra, bone diseases | |
| KR20180127780A (en) | Chinese medicine for treating hyperostosis | |
| CN1079029C (en) | Medical capsule for treating bone rheumatism and preparing process | |
| CN106361947A (en) | Preparation method of traditional Chinese medicine for treating osteoporosis | |
| CN101904958B (en) | Oral medicinal composition for treating fracture | |
| CN104524524B (en) | Medicine treating osteoporosis and preparing method | |
| CN103735958B (en) | Medicine for the treatment of osteoproliferation, spur, disc herniation and preparation method thereof | |
| CN114796162A (en) | Plaster for treating bone fracture and arthralgia and myalgia and preparation method thereof | |
| DE102016103555A1 (en) | Chinese medicine for the treatment of hyperostosis | |
| KR20180125770A (en) | Chinese medicine for treating hyperostosis | |
| KR20180137229A (en) | Chinese medicine for treating hyperostosis | |
| KR20180138391A (en) | Chinese medicine for treating hyperostosis | |
| CN106038875A (en) | Traditional Chinese medicine plaster for treating cervical spondylosis and preparation method thereof | |
| KR20180136081A (en) | Chinese medicine for treating hyperostosis | |
| CN104491828A (en) | Warming pain relief Chinese materia medica preparation and paste preparing method thereof | |
| KR20190001364A (en) | Chinese medicine for treating hyperostosis | |
| KR20180137759A (en) | Chinese medicine for treating hyperostosis | |
| DE102017113000A1 (en) | Chinese drug for the treatment of hyperostosis | |
| CN106177775A (en) | A kind of Chinese medicine composition treating hyperosteogeny | |
| CN103656309A (en) | Auxiliary drug composition for bone fracture/bony crack healing | |
| CN104435994A (en) | Traditional Chinese medicine for treating hyperosteogeny arthritis and preparation method thereof | |
| CN105168545A (en) | Angelica sinensis spur traditional Chinese medicine wine | |
| CN106389529A (en) | Miao medicine for treating cold lumbago | |
| CN105596628A (en) | Physiotherapy water with tendon relaxing and blood circulation activating efficacy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20170522 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200302 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20170522 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20201223 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20210312 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20201223 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |